Sona Nanotech Approved for Funding Support to Develop a Bovine Tuberculosis Rapid Test
Halifax, Nova Scotia--(Newsfile Corp. - May 20, 2021) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona"), a developer of rapid, point-of-care diagnostic tests, is pleased to announce that it is receiving advisory services and up to $457,830 in funding support from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support a research project in association with a consortium of UK companies to develop a bovine tuberculosis ("bTB")...
2021-05-20 9:00 AM EDT
Sona to Commence Clinical Trial for COVID-19 Rapid Saliva Test
Halifax, Nova Scotia--(Newsfile Corp. - April 22, 2021) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") a developer of rapid, point-of-care diagnostic tests is pleased to announce that it has received research ethics board approval for its clinical trial of the Sona Saliva C-19 Rapid Test. The trial, which will seek to test up to 500 emergency room patients suspected of having COVID-19, is expected to commence next week. The Company will update the market...
2021-04-22 4:50 PM EDT
Sona Secures Clinical Trial Authorization and Hospital Partner
Halifax, Nova Scotia--(Newsfile Corp. - April 12, 2021) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona"), a developer of rapid, point-of-care diagnostic tests is pleased to announce that it has been granted Health Canada Investigational Testing Authorization for a clinical trial of the Sona Saliva C-19 Rapid Test, a saliva sample-based rapid COVID-19 antigen test, with the Humber River Hospital in Toronto. The trial is expected to commence shortly, following final...
2021-04-12 9:13 PM EDT
Sona Establishes an At-The-Market Common Share Offering
Halifax, Nova Scotia--(Newsfile Corp. - April 9, 2021) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") a developer of rapid, point-of-care diagnostic tests announces that pursuant to an equity distribution agreement (the "Equity Distribution Agreement") with Canaccord Genuity Corp., the Company may, from time to time, sell up to $10 million of common shares ("Common Shares") in the capital of the Company (the "ATM Offering"). The Company intends to use the net...
2021-04-09 7:53 PM EDT
Sona Announces Filing of Preliminary Short Form Base Shelf Prospectus
Halifax, Nova Scotia--(Newsfile Corp. - March 23, 2021) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") a developer of rapid, point-of-care diagnostic tests, has filed a preliminary short form base shelf prospectus (the "Shelf Prospectus") with the securities regulatory authorities in each of the provinces and territories of Canada. The objective of filing the Shelf Prospectus is to provide the Company with the financial flexibility to take advantage of financing...
2021-03-23 4:11 PM EDT
Sona Nanotech Receives CE Mark Approval for its Rapid COVID-19 Antigen Test
Halifax, Nova Scotia--(Newsfile Corp. - December 31, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company", "Sona") a developer of rapid, point-of-care diagnostic tests, has been granted CE Mark status for its rapid, COVID-19 antigen test. The CE Mark declares the conformity of the Sona test with EU regulations and allows Sona to commercialize its test throughout Europe and potentially other territories in which the CE Mark is recognized.The Company intends to begin selling...
2020-12-31 9:08 AM EST
Sona Nanotech Closes Unbrokered Private Placement Financing for $2.26M in Gross Proceeds
Halifax, Nova Scotia--(Newsfile Corp. - December 16, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company", "Sona") a developer of rapid, point-of-care diagnostic tests, is pleased to announce that it has closed its non-brokered private placement that was announced on December 3, 2020 with the issuance of 2,259,200 units at $1.00 per unit.The final amount of the offering represents an increase from the Company's previously announced intention to raise up to $2,000,000 through...
2020-12-16 9:32 AM EST
Sona Nanotech Comments on Market Activity
Halifax, Nova Scotia--(Newsfile Corp. - December 10, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company", "Sona") a developer of rapid, point-of-care diagnostic tests, at the request of Investment Industry Regulatory Organization of Canada (IIROC), confirms that it is not aware of any reason for today's increase in market activity in its shares and there has been no material change or information to report under applicable securities laws that would account for today's...
2020-12-10 1:09 PM EST
Sona Nanotech $2M Private Placement Financing Fully Subscribed
Halifax, Nova Scotia--(Newsfile Corp. - December 8, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") a developer of rapid, point-of-care diagnostic tests, is pleased to announce that its previously announced non-brokered private placement for up to $2,00,000 is now fully subscribed. The Company expects to close the Financing shortly. The Company previously announced its intention to raise up to $2,000,000 through a non-brokered private placement (the "Financing")...
2020-12-08 9:35 AM EST
Sona Nanotech Arranges Private Placement Financing and Appoints EU Agent for Application for CE Mark
Halifax, Nova Scotia--(Newsfile Corp. - December 3, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") a developer of rapid, point-of-care diagnostic tests, is pleased to announce that it plans to raise up to $2,000,000 through a non-brokered private placement (the "Financing") of up to 2,000,000 units of Sona (each, a "Unit") at $1.00 per Unit. Each Unit will consist of one common share of Sona (a "Common Share") and one-half of a Common Share purchase...
2020-12-03 9:00 AM EST
Sona Nanotech Provides Corporate Update
Halifax, Nova Scotia--(Newsfile Corp. - November 30, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company"), a developer of rapid, point-of-care diagnostic tests, received further feedback from Health Canada, subsequent to its withdrawal of its application for an Interim Order authorization ("IO") for the marketing of its rapid, COVID-19 antigen test. As part of its review, Health Canada commissioned an evaluation from the National Microbiology Laboratory (NML) whose evaluation...
2020-11-30 8:58 AM EST
Sona Nanotech Withdraws Rapid COVID-19 Antigen Test Application Based on Feedback from Health Canada
Halifax, Nova Scotia--(Newsfile Corp. - November 25, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company"), a developer of rapid, point-of-care diagnostic tests, withdrew its application for an Interim Order authorization ("IO") from Health Canada for the marketing of its rapid, COVID-19 antigen test in order to obtain more clinical data to augment its submission. The Company is committed to working with regulators to provide additional information and analysis on its test and...
2020-11-25 1:50 PM EST
Sona Nanotech Appoints New Director
Halifax, Nova Scotia--(Newsfile Corp. - November 3, 2020) - Sona Nanotech Inc. (CSE: SONA) (the "Company") is pleased to announce the appointment of Mr. J. Mark Lievonen, C.M., to the Company's Board of Directors. Mr. Lievonen is the former President of Sanofi Pasteur Limited, the Canadian vaccine division of Sanofi. Under his leadership, Sanofi Pasteur became a billion dollar enterprise in Canada, manufacturing over 50 million doses of vaccines for both domestic and international markets....
2020-11-03 8:18 AM EST
Sona Nanotech Receives 'Deprioritization' from FDA; Health Canada Evaluation Continues
Halifax, Nova Scotia--(Newsfile Corp. - October 29, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company"), a developer of rapid, point-of-care diagnostic tests, received notice from the FDA that the Company's request for an emergency use authorization ("EUA") for the marketing of its rapid COVID-19 antigen test in the United States "is not a priority" and consequently such authorization will not be issued at this time. The FDA cited current EUA request prioritization criteria...
2020-10-29 8:38 AM EDT
Sona Engages Sports Marketing Partner to Secure Concussion Test Development Partner
Halifax, Nova Scotia--(Newsfile Corp. - August 31, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company"), a developer of rapid, point-of-care diagnostic tests, announced today it has engaged Bonham/Wills & Associates ("Bonham/Wills"), a leading sports consulting firm, to assist in securing test development sponsorship partners for its next rapid-response test R&D project, leveraging the Company's proprietary gold nanorod technology. Bonham/Wills is tasked with identifying...
2020-08-31 8:15 AM EDT
Sona Nanotech Announces Clinical Evaluation Study Results for its COVID-19 Antigen Test
Halifax, Nova Scotia--(Newsfile Corp. - August 25, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company"), a developer of rapid, point-of-care diagnostic tests, is pleased to announce that its rapid detection COVID-19 antigen test achieved a sensitivity of 84.6% and a specificity of 90.0% in a study across 99 collected clinical patient samples, which included 39 positive samples and 60 negative samples, as determined by RT-PCR testing. The Company is now continuing its...
2020-08-25 1:34 PM EDT
Sona Nanotech Clinical In-Field Validation Study Results to Be Released Next Week
Halifax, Nova Scotia--(Newsfile Corp. - August 20, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company"), a developer of rapid, point-of-care diagnostic tests, announces that it expects to release a report on its clinical, in-field evaluation studies for its rapid detection, COVID-19 antigen test next week. This data will be used to support the Company's submissions to Health Canada and the FDA for emergency use authorization ("EUA") approval for its COVID-19 antigen test.The...
2020-08-20 9:38 AM EDT
Sona Nanotech Updates on Timing of Clinical In-Field Validation Studies for its COVID-19 Antigen Test
Halifax, Nova Scotia--(Newsfile Corp. - August 6, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company"), a developer of rapid, point-of-care diagnostic tests, announces that its previously announced clinical, in-field evaluation studies for its rapid detection, COVID-19 antigen test that commenced in July continue and are now expected to return their full results within two weeks. The delays have been due to ethics review board approvals and a need to make study modifications...
2020-08-06 1:51 PM EDT
Sona Nanotech Unaware of Any Material Change
Halifax, Nova Scotia--(Newsfile Corp. - July 23, 2020) - At the request of the Investment Industry Regulatory Organization of Canada ("IIROC") Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company") wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent increase in market activity.The Company cautions that its COVID-19 rapid antigen test is not yet approved by the FDA or other regulatory bodies and...
2020-07-23 3:03 PM EDT
RETRANSMISSION: Sona Nanotech Engages Maxim Group for NASDAQ Listing and Investment Banking Services, and Announces Organizational Change
Halifax, Nova Scotia--(Newsfile Corp. - July 9, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) ("Sona Nanotech" or the "Company"), a developer of rapid, point-of-care diagnostic tests for COVID-19 and other applications, has engaged Maxim Group, LLC ("Maxim") for general financial advisory and investment banking services in relation to its planned application to list the Company's common shares on the NASDAQ Capital Market ("NASDAQ").By up-listing to NASDAQ, the Company aspires to...
2020-07-09 8:00 AM EDT